NAS:AGEN (USA) Also Trade In: Germany

Agenus Inc $ 3.90 0.46 (13.37%)

Volume:
4,787,296
Avg Vol (1m):
2,206,014
Market Cap $:
741.58 Mil
Enterprise Value $:
656.35 Mil
P/E (TTM):
0.00
P/B:
0.00
Warning! GuruFocus has detected 4 Severe warning signs with AGEN. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Agenus Inc () from 2000 to Jan 25 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Agenus stock (AGEN) PE ratio as of Jan 25 2021 is 0. More Details

Agenus PE Ratio (TTM) Chart

EMBED

Agenus PE Ratio (TTM) Historical Data

Total 1259
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Agenus PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-01-260.0 2020-11-240.0
2021-01-250.0 2020-11-230.0
2021-01-220.0 2020-11-200.0
2021-01-210.0 2020-11-190.0
2021-01-200.0 2020-11-180.0
2021-01-190.0 2020-11-170.0
2021-01-180.0 2020-11-160.0
2021-01-150.0 2020-11-130.0
2021-01-140.0 2020-11-120.0
2021-01-130.0 2020-11-110.0
2021-01-120.0 2020-11-100.0
2021-01-110.0 2020-11-090.0
2021-01-080.0 2020-11-060.0
2021-01-070.0 2020-11-050.0
2021-01-060.0 2020-11-040.0
2021-01-050.0 2020-11-030.0
2021-01-040.0 2020-11-020.0
2021-01-010.0 2020-10-300.0
2020-12-310.0 2020-10-290.0
2020-12-300.0 2020-10-280.0
2020-12-290.0 2020-10-270.0
2020-12-280.0 2020-10-260.0
2020-12-250.0 2020-10-230.0
2020-12-240.0 2020-10-220.0
2020-12-230.0 2020-10-210.0
2020-12-220.0 2020-10-200.0
2020-12-210.0 2020-10-190.0
2020-12-180.0 2020-10-160.0
2020-12-170.0 2020-10-150.0
2020-12-160.0 2020-10-140.0
2020-12-150.0 2020-10-130.0
2020-12-140.0 2020-10-120.0
2020-12-110.0 2020-10-090.0
2020-12-100.0 2020-10-080.0
2020-12-090.0 2020-10-070.0
2020-12-080.0 2020-10-060.0
2020-12-070.0 2020-10-050.0
2020-12-040.0 2020-10-020.0
2020-12-030.0 2020-10-010.0
2020-12-020.0 2020-09-300.0
2020-12-010.0 2020-09-290.0
2020-11-300.0 2020-09-280.0
2020-11-270.0 2020-09-250.0
2020-11-260.0 2020-09-240.0
2020-11-250.0 2020-09-230.0

Agenus PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325414 NAICS : 2836
Traded in other countries AJ81.Germany AGEN.USA
Address 3 Forbes Road, Lexington, MA, USA, 02421-7305
Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.